Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Topical Dorzolamide and Latanoprost on Refraction in Glaucoma
IRCT2013052813505N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jun 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dorzolamide and latanoprost in Glaucoma, sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Change in refraction. Started Jun 2013; status: completed.
02
Drugs
dorzolamidelatanoprost
03
Conditions
Glaucoma
Beyond the preview
Go deeper on IRCT2013052813505N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2013052813505N1.